TrialDiabetes, obesity & metabolism2018

Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS).

Yasuo Terauchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.